-
-
-
-
-
-
-
Leerink Resumes Genmab A/S (GMAB) at Outperform
-
-
-
-
-
-
-
Genmab A/S (GMAB) PT Raised to $40 at H.C. Wainwright
-
-
-
-
-
-
-
Genmab reduces share capital by DKK 1.9 million through cancellation
-
-
-
-
-
-
-
Jefferies sees a 'catalyst-rich' path for this pharma stock
-
-
-
-
-
-
-
Genmab A/S (GMAB) PT Lowered to $39 at H.C. Wainwright
-
-
-
-
-
-
-
This pharma stock has 3 'material catalysts' in 2026: BofA
-
-
-
-
-
-
-
Genmab reports DARZALEX net sales of $3.67 billion in Q3 2025
-
483,150 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


